Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAtla, Inc.BCAB · Entity 879 | Director | June 18, 2025 | June 18, 2025 |
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | Director | June 02, 2026 | June 03, 2026 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director | May 28, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAtla, Inc.
Report date June 18, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,307 |
Reported balance
After 2025-06-18 transaction · row 1
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 23,500 · Balance 52,307 F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.
CRESCENT BIOPHARMA, INC.
Report date June 02, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.01 · Expires 2036-06-02 | Direct | 11,050 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 11,050 · Balance 11,050 F1: This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Tyra Biosciences, Inc.
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.68 · Expires 2036-05-27 | Direct | 13,160 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 13,160 · Balance 13,160 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RayzeBio, Inc.
Report date February 26, 2024 · Filed February 27, 2024
Section 16 reporting ended · disclosed 2024-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 1
1 source rowRow 1 · 2024-02-26 · Disposition to issuer · Disposed 323,455 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount. F2: Includes 808 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on February 22, 2024. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2031-09-28 | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-26 · Disposition to issuer · Disposed 60,757 · Balance 0 F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2031-12-14 | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-26 · Disposition to issuer · Disposed 77,805 · Balance 0 F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2032-11-30 | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-26 · Disposition to issuer · Disposed 194,514 · Balance 0 F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.72 · Expires 2033-11-16 | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-26 · Disposition to issuer · Disposed 164,000 · Balance 0 F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount.
F2: Includes 808 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on February 22, 2024.
F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 3, 2026 23:47 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 11,050 | $0.00 Strike: $17.01 | $0.00 |
DisclosureSEC source: 0001628280-26-040577 · wk-form4_1780530428.xml · derivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,050 Underlying: Ordinary Shares · 11,050 shares Expires 2036-06-02 F1 · derivative.exercise_date: This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 13,160 | $0.00 Strike: $32.68 | $0.00 |
DisclosureSEC source: 0001193125-26-251538 · ownership.xml · derivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,160 Underlying: Common Stock · 13,160 shares Expires 2036-05-27 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 23, 2025 Filed Jun 23, 2025 22:51 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 9,023 | $0.00 Strike: $15.30 | $0.00 |
DisclosureSEC source: 0001104659-25-061820 · tm2518376-18_4seq1.xml · derivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,023 Underlying: Ordinary Shares · 9,023 shares Expires 2035-06-23 F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 18, 2025 23:45 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 23,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-088065 · ownership.xml · nonDerivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,307 F1 · shares: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:05 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 22,200 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0000950170-25-080228 · ownership.xml · derivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,200 Underlying: Common Stock · 22,200 shares Expires 2035-05-28 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:13 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073659 · ownership.xml · nonDerivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,807 F1 · shares: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 13, 2025, and (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock (Right to Buy) · Derivative | 37,200 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0000950170-24-057201 · ownership.xml · derivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,200 Underlying: Common Stock · 37,200 shares Expires 2034-05-06 F1 · derivative.exercise_date: 1/36th of the total number of shares of common stock subject to the option vest monthly following May 7, 2024, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 16:45 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 164,000 | Not disclosed Strike: $22.72 | Not disclosed |
DisclosureSEC source: 0001415889-24-005507 · form4-02272024_090249.xml · derivative · entry 5 Moran Susan · CIK 0001835225 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164,000 shares Expires 2033-11-16 F3 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 16:45 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 194,514 | Not disclosed Strike: $3.24 | Not disclosed |
DisclosureSEC source: 0001415889-24-005507 · form4-02272024_090249.xml · derivative · entry 4 Moran Susan · CIK 0001835225 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 194,514 shares Expires 2032-11-30 F3 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 16:45 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 77,805 | Not disclosed Strike: $3.24 | Not disclosed |
DisclosureSEC source: 0001415889-24-005507 · form4-02272024_090249.xml · derivative · entry 3 Moran Susan · CIK 0001835225 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,805 shares Expires 2031-12-14 F3 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 16:45 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 60,757 | Not disclosed Strike: $3.24 | Not disclosed |
DisclosureSEC source: 0001415889-24-005507 · form4-02272024_090249.xml · derivative · entry 2 Moran Susan · CIK 0001835225 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,757 shares Expires 2031-09-28 F3 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 16:45 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerCommon Stock | 323,455 | $62.50 | $20,215,937.50 |
DisclosureSEC source: 0001415889-24-005507 · form4-02272024_090249.xml · nonDerivative · entry 1 Moran Susan · CIK 0001835225 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount. F2 · shares: Includes 808 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on February 22, 2024. Read SEC document |
| January 22, 2024 Filed Feb 6, 2024 18:11 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,875 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001415889-24-002852 · form4-02062024_110254.xml · derivative · entry 2 Moran Susan · CIK 0001835225 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,757 Underlying: Common Stock · 30,875 shares Expires 2031-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. 25% of the shares vested on September 29, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| January 22, 2024 Filed Feb 6, 2024 18:11 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Exercise / conversionCommon Stock | 30,875 | $3.24 | $100,035.00 |
DisclosureSEC source: 0001415889-24-002852 · form4-02062024_110254.xml · nonDerivative · entry 1 Moran Susan · CIK 0001835225 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2023 Filed Nov 17, 2023 18:36 UTC | RayzeBio, Inc. RYZB · Entity 93779 | GrantStock Option (right to buy) · Derivative | 164,000 | $0.00 Strike: $22.72 | $0.00 |
DisclosureSEC source: 0001628280-23-039535 · wk-form4_1700264163.xml · derivative · entry 1 Moran Susan · CIK 0001835225 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2033-11-16 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments over the four-year period measured from the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 22:41 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001209191-23-037547 · doc4.xml · derivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 14, 2024 or (b) the day before the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 23:51 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-22-038170 · doc4.xml · derivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 16, 2023 or (b) the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 01:34 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (right to buy) · Derivative | 12,307 | $0.00 Strike: $39.64 | $0.00 |
DisclosureSEC source: 0001209191-21-041227 · doc4.xml · derivative · entry 1 Moran Susan · CIK 0001835225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,307 Underlying: Common Stock · 12,307 shares Expires 2031-06-15 F1 · derivative.exercise_date: 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 15, 2022 or (b) the next annual meeting of stockholders, subject to the Optionee continuing to provide services to the Company through the vesting date; provided however, that if the Optionee ceases to provide services to the Company prior to the vesting date for any reason other than Cause (as defined in the Plan), such Option will vest on a pro-rata basis determined by multiplying the total number of shares by a fraction, the numerator of which is the number of whole months that the Optionee provided services to the Company since the date that the award was granted, and the denominator of which is 12 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.